Shaping the future of innovative vaccination against leptospirosis

July 24, 2017

CALIXAR and its partners celebrated on June 12th 2017 the completion of their successful partnership within the consortium COVALEPT coordinated by BOEHRINGER INGELHEIM. The multi-expertise 4-year project allowed the generation of high impact data in view of producing a better leptospirosis vaccine candidate.

Building on the success of this consortium, members have jointly expressed their wish to maintain an active partnership to pursue improvement of current vaccines.

CALIXAR was involved in the identification of markers of virulence and also the production of identified native antigens from native and/or recombinant bacteria while conserving their native state. COVALEPT is a multidisciplinary and very collaborative project that CALIXAR was happy to conduct and pursue.

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.